

Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Kluger HM, Tawbi H, Feltquate D, *et al.* Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. *J Immunother Cancer* 2023;11:e007309. doi: 10.1136/jitc-2023-007309.

This article has been corrected since it was first published online. The author order was incorrect and has now been updated to the following: Hussein A Tawbi, Ryan J Sullivan, David Feltquate, Naiyer A Rizvi, Elad Sharon, Jeffrey Sosman, Harriet M Kluger. HAT and RJS contributed equally.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2023;11:e007309corr1. doi:10.1136/jitc-2023-007309corr1

